306 related articles for article (PubMed ID: 27317099)
1. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB
J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099
[TBL] [Abstract][Full Text] [Related]
2. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway.
Shu YJ; Weng H; Ye YY; Hu YP; Bao RF; Cao Y; Wang XA; Zhang F; Xiang SS; Li HF; Wu XS; Li ML; Jiang L; Lu W; Han BS; Jie ZG; Liu YB
Mol Cancer; 2015 Jan; 14(1):12. PubMed ID: 25623055
[TBL] [Abstract][Full Text] [Related]
3. Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.
Cao Y; Liang H; Zhang F; Luan Z; Zhao S; Wang XA; Liu S; Bao R; Shu Y; Ma Q; Zhu J; Liu Y
J Exp Clin Cancer Res; 2016 Apr; 35():68. PubMed ID: 27084680
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
5. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.
Shen H; He M; Lin R; Zhan M; Xu S; Huang X; Xu C; Chen W; Yao Y; Mohan M; Wang J
J Exp Clin Cancer Res; 2019 Jun; 38(1):247. PubMed ID: 31182136
[TBL] [Abstract][Full Text] [Related]
6. TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway.
Zhang Y; Du P; Li Y; Zhu Q; Song X; Liu S; Hao J; Liu L; Liu F; Hu Y; Jiang L; Ma Q; Lu W; Liu Y
Int J Biol Sci; 2020; 16(5):739-751. PubMed ID: 32071545
[TBL] [Abstract][Full Text] [Related]
7. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SNORA21 suppresses tumorgenesis of gallbladder cancer in vitro and in vivo.
Qin Y; Zhou Y; Ge A; Chang L; Shi H; Fu Y; Luo Q
Biomed Pharmacother; 2019 Oct; 118():109266. PubMed ID: 31401397
[TBL] [Abstract][Full Text] [Related]
9. STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma.
Hu YP; Wu ZB; Jiang L; Jin YP; Li HF; Zhang YJ; Ma Q; Ye YY; Wang Z; Liu YC; Chen HZ; Liu YB
Int J Biochem Cell Biol; 2018 Apr; 97():16-27. PubMed ID: 29413947
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-related receptor-α promotes gallbladder cancer development by enhancing the transcription of Nectin-4.
Wang L; Yang M; Guo X; Yang Z; Liu S; Ji Y; Jin H
Cancer Sci; 2020 May; 111(5):1514-1527. PubMed ID: 32030850
[TBL] [Abstract][Full Text] [Related]
11. A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth.
Zhang Y; Liu S; Wang L; Wu Y; Hao J; Wang Z; Lu W; Wang XA; Zhang F; Cao Y; Liang H; Li H; Ye Y; Ma Q; Zhao S; Shu Y; Bao R; Jiang L; Hu Y; Zhou J; Chen L; Liu Y
Cancer Lett; 2016 May; 375(1):179-189. PubMed ID: 26949052
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II alpha promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.
Lyu WJ; Shu YJ; Liu YB; Dong P
Chin Med J (Engl); 2020 Oct; 133(19):2321-2329. PubMed ID: 32925281
[TBL] [Abstract][Full Text] [Related]
13. Desulfation of cell surface HSPG is an effective strategy for the treatment of gallbladder carcinoma.
Yi B; Qiu Y; Ji W; Wei M; Liu C; Peng Z; Zhang Y; Quan Z; Tang Z; Su C
Cancer Lett; 2016 Oct; 381(2):349-58. PubMed ID: 27502167
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.
Cao Y; Liu X; Lu W; Chen Y; Wu X; Li M; Wang XA; Zhang F; Jiang L; Zhang Y; Hu Y; Xiang S; Shu Y; Bao R; Li H; Wu W; Weng H; Yen Y; Liu Y
Cancer Lett; 2015 May; 360(2):141-50. PubMed ID: 25657110
[TBL] [Abstract][Full Text] [Related]
15. Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor.
Lee HJ; Lee K; Lee DG; Bae KH; Kim JS; Liang ZL; Huang SM; Suk Oh Y; Kim HY; Jo DY; Min JK; Kim JM; Lee HJ
Clin Cancer Res; 2012 Jun; 18(12):3270-80. PubMed ID: 22553346
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA SPRY4-IT1 promotes gallbladder carcinoma progression.
Yang L; Cheng X; Ge N; Guo W; Feng F; Wan F
Oncotarget; 2017 Jan; 8(2):3104-3110. PubMed ID: 27902971
[TBL] [Abstract][Full Text] [Related]
17. EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
Moon A; Chin S; Kim HK; Kwak JJ; Koh ES; Kim YW; Jang KT
Pathology; 2016 Jan; 48(1):35-40. PubMed ID: 27020207
[TBL] [Abstract][Full Text] [Related]
18. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Additional Options for an Orphan Cancer.
Roa I; Garcia H; Game A; de Toro G; de Aretxabala X; Javle M
J Mol Diagn; 2016 May; 18(3):388-394. PubMed ID: 26947513
[TBL] [Abstract][Full Text] [Related]
19. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.
Lee DG; Lee SH; Kim JS; Park J; Cho YL; Kim KS; Jo DY; Song IC; Kim N; Yun HJ; Park YJ; Lee SJ; Lee HG; Bae KH; Lee SC; Shim S; Kim YM; Kwon YG; Kim JM; Lee HJ; Min JK
J Hepatol; 2015 Dec; 63(6):1429-39. PubMed ID: 26292259
[TBL] [Abstract][Full Text] [Related]
20. Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer.
Hirosawa T; Ishida M; Ishii K; Kanehara K; Kudo K; Ohnuma S; Kamei T; Motoi F; Naitoh T; Selaru FM; Unno M
PLoS One; 2018; 13(11):e0206643. PubMed ID: 30395583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
